Back to top
more

Vir Biotechnology (VIR)

(Delayed Data from NSDQ)

$8.23 USD

8.23
1,106,208

+0.60 (7.86%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pediatrix Medical (MD) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Pediatrix Medical's (MD) fourth-quarter results are likely to reflect higher operating expenses and patient volume growth.

GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook

by Zacks Equity Research

GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.

GSK Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.

Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.

FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld

by Zacks Equity Research

AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.

Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Editas (EDIT) Moves Ahead With its Portfolio Reprioritization

by Zacks Equity Research

Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.

Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.

3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

by Zacks Equity Research

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

Should Value Investors Buy Vir Biotechnology (VIR) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

by Zacks Equity Research

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.

Is Biogen (BIIB) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 70.9% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Should Value Investors Buy Vir Biotechnology (VIR) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sanghamitra Saha headshot

5 Winning Stocks Backed by the Overlooked Rising P/E Trick

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).

Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Predict a 107% Upside in Vir Biotechnology, Inc. (VIR): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 107.4% in Vir Biotechnology, Inc. (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Vir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GSK Gears Up to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales.

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 31.94% and 15.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract

by Zacks Equity Research

VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.

Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More

by Zacks Equity Research

Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.

GSK's Key Drugs to Drive Sales in a Sluggish Second Half

by Zacks Equity Research

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.